Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

495 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression in elderly patients: a subgroup analysis of HOT/NJLCG2001.
Tateishi K, Mizugaki H, Ikezawa Y, Morita R, Yokoo K, Sumi T, Aso M, Kikuchi H, Nakamura A, Sekikawa M, Yoshiike F, Kitamura Y, Kimura N, Hachiya T, Tsurumi K, Agatsuma T, Megumi F, Nakamura K, Jingu D, Yamamoto H, Kosaka M, Yokouchi H. Tateishi K, et al. Among authors: hachiya t. Jpn J Clin Oncol. 2024 Dec 4:hyae168. doi: 10.1093/jjco/hyae168. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39656678
Anti-integrin αvβ6 autoantibody in primary sclerosing cholangitis: a Japanese nationwide study.
Yasuda M, Shiokawa M, Kuwada T, Nishikawa Y, Nakanishi R, Takimoto I, Chikugo K, Yokode M, Muramoto Y, Matsumoto S, Nakamura T, Ota S, Matsumori T, Kuroda K, Hachiya T, Yamazaki H, Uza N, Kodama Y, Chiba T, Fujisawa T, Komori A, Abe M, Yamaguchi I, Matsuda F, Isayama H, Tanaka A, Seno H; Japan PSC Study Group (JPSCSG). Yasuda M, et al. Among authors: hachiya t. J Gastroenterol. 2024 Nov 16. doi: 10.1007/s00535-024-02169-w. Online ahead of print. J Gastroenterol. 2024. PMID: 39549066
Evaluation of the association between predictive factors and the development of immune-related adverse events and prognostic factors for chemoimmunotherapy in patients with non-small cell lung cancer: A multicenter retrospective study.
Ozawa R, Sonehara K, Hachiya T, Nozawa S, Agatsuma T, Yamamoto H, Kato A, Matsuo A, Hirabayashi T, Araki T, Komatsu M, Tateishi K, Hanaoka M. Ozawa R, et al. Among authors: hachiya t. Cancer Med. 2024 Aug;13(15):e70080. doi: 10.1002/cam4.70080. Cancer Med. 2024. PMID: 39096117 Free PMC article.
Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis.
Ikezawa Y, Morita R, Mizugaki H, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Nakamura A, Kobayashi M, Aso M, Kimura N, Yoshiike F, Megumi F, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Hommura F, Sukoh N, Ito K, Kikuchi T, Agatsuma T, Yokouchi H. Ikezawa Y, et al. Among authors: hachiya t. Cancer Med. 2024 Jul;13(14):e70036. doi: 10.1002/cam4.70036. Cancer Med. 2024. PMID: 39030894 Free PMC article.
495 results